Reported Standalone quarterly numbers for Sun Pharma Advanced Research Company are:
Net Sales at Rs 16.56 crore in March 2024 down 65.28% from Rs. 47.69 crore in March 2023.
Story continues below Advertisement
Quarterly Net Loss at Rs. 106.69 crore in March 2024 down 30.13% from Rs. 81.99 crore in March 2023.
EBITDA stands negative at Rs. 103.12 crore in March 2024 down 30.8% from Rs. 78.84 crore in March 2023.
Sun Pharma Adv shares closed at 223.65 on May 24, 2024 (NSE) and has given -18.09% returns over the last 6 months and 20.92% over the last 12 months.
Story continues below Advertisement
| Sun Pharma Advanced Research Company | | Standalone Quarterly Results | in Rs. Cr. |
|
| Mar'24 | Dec'23 | Mar'23 | | Net Sales/Income from operations | 16.56 | 13.86 | 47.69 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 16.56 | 13.86 | 47.69 | | EXPENDITURE | | Consumption of Raw Materials | 7.46 | 9.03 | 5.78 | | Purchase of Traded Goods | -- | -- | -- | | Increase/Decrease in Stocks | -- | -- | -- | | Power & Fuel | -- | -- | -- | | Employees Cost | 26.72 | 29.98 | 29.90 | | Depreciation | 2.69 | 3.16 | 2.94 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 89.90 | 77.47 | 101.58 | | P/L Before Other Inc. , Int., Excpt. Items & Tax | -110.21 | -105.78 | -92.51 | | Other Income | 4.40 | 6.39 | 10.73 | | P/L Before Int., Excpt. Items & Tax | -105.81 | -99.39 | -81.78 | | Interest | 0.88 | 0.26 | 0.21 | | P/L Before Exceptional Items & Tax | -106.69 | -99.65 | -81.99 | | Exceptional Items | -- | -- | -- | | P/L Before Tax | -106.69 | -99.65 | -81.99 | | Tax | -- | -- | -- | | P/L After Tax from Ordinary Activities | -106.69 | -99.65 | -81.99 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | -106.69 | -99.65 | -81.99 | | Equity Share Capital | 32.45 | 32.45 | 32.45 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | -3.29 | -3.07 | -2.55 | | Diluted EPS | -3.29 | -3.07 | -2.55 | | EPS After Extra Ordinary | | Basic EPS | -3.29 | -3.07 | -2.55 | | Diluted EPS | -3.29 | -3.07 | -2.55 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
